Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 15NIH 10NETWORK 3INDUSTRY 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 48Gynecologic 47CNS 7Other solid neoplasm 5Sarcoma 4Tumor-Agnostic 2Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Leukemia, Myeloid, Acute 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Topotecan × Other hematologic neoplasm × Clear all
NCT04029688 2024-12-20

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Hoffmann-La Roche

Phase 1/2 Terminated
38 enrolled 34 charts
CNSLymphoidOther hematologic neoplasm

Neuroblastoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡